Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CinCor Pharma, Inc. CINC
$29.06
На 18:04, 12 мая 2023
+66.90%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1271790558.00000000
-
week52high
43.15
-
week52low
10.53
-
Revenue
0
-
P/E TTM
-13
-
Beta
0.00000000
-
EPS
-2.01000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 ноя 2022 г. в 11:15
Описание компании
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | 22 авг 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 09 авг 2022 г. |
| Oppenheimer | Outperform | Outperform | 21 июл 2022 г. |
| Morgan Stanley | Overweight | Overweight | 15 июл 2022 г. |
| Oppenheimer | Outperform | 01 февр 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 09 сент 2022 г. |
| Goldman Sachs | Buy | 28 окт 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 10 янв 2023 г. |
| Barclays | Overweight | 08 дек 2022 г. | |
| Barclays | Overweight | 07 дек 2022 г. | |
| Oppenheimer | Perform | Outperform | 29 ноя 2022 г. |
| Morgan Stanley | Equal-Weight | Overweight | 29 ноя 2022 г. |
| Barclays | Equal-Weight | Overweight | 12 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Pearce Catherine | A | 155149 | 15000 | 26 янв 2023 г. |
| de Garidel Marc | A | 212500 | 200000 | 26 янв 2023 г. |
| Freeman Mason | A | 42500 | 40000 | 26 янв 2023 г. |
| Kalb Michael Wayne | A | 202437 | 177000 | 26 янв 2023 г. |
| Pearce Catherine | D | 13236 | 13235 | 11 янв 2023 г. |
| Pearce Catherine | D | 140149 | 3997 | 11 янв 2023 г. |
| Pearce Catherine | A | 144146 | 13235 | 11 янв 2023 г. |
| Allison David D. | A | 1499 | 1499 | 06 янв 2023 г. |
| Kalb Michael Wayne | A | 77615 | 77615 | 04 ноя 2022 г. |
| Kalb Michael Wayne | A | 25437 | 25437 | 04 ноя 2022 г. |
Новостная лента
Why Is CinCor (CINC) Stock Up 138% Today?
InvestorPlace
09 янв 2023 г. в 10:42
CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has it agreeing to a tender offer of $26 per share for CINC stock.
AstraZeneca to acquire CinCor for US$1.8bn
Proactive Investors
09 янв 2023 г. в 07:09
AstraZeneca PLC (LSE:AZN) has announced it will acquire US-based biopharmaceutical firm CinCor for approximately US$1.8bn in an effort to boost its treatments of cardiorenal diseases. As part of the deal, AstraZeneca will also acquire CinCor's cash and marketable securities, valued at US$522mln late September.
AstraZeneca to Buy CinCor Pharma in $1.8 Billion Deal
Barrons
09 янв 2023 г. в 04:32
AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
AstraZeneca to buy U.S.-based CinCor Pharma in $1.8 bln deal
Reuters
09 янв 2023 г. в 02:16
AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
These Were the 5 Best and Worst Performing Small-Cap Stocks in November 2022
24/7 Wall Street
13 дек 2022 г. в 22:55
Investing in small-cap stocks is usually a very risky business, but they could offer quick and hefty returns.